David Josephson, MD
Urology · Los Angeles, CANPI 1063510840
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Intuitive Surgical at 47.0% of the total. Reporting peaked in 2019 at $13,772 and has fallen 76.7% since, to $3,208 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $158.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$23K
- AbbVie$10K
- Progenics Pharmaceuticals, Inc.$3K
- Antares Pharma, Inc.$3K
- Blue Earth Diagnostics$2K
- Cipla USA Inc.$674
- plus $7K from 40 others
Across 112 payments — averaging $12,508 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blue Earth Diagnostics$695K
- Progenics Pharmaceuticals, Inc.$620K
- Sumitomo Pharma America, Inc.$39K
- Astrazeneca UK Limited$20K
- Bayer$14K
- Urogen Pharma, Inc.$13K
What the payments were for
- Consulting fees$4,99510%
- Speaking & faculty fees$10,80022%
- Travel & lodging$2,3495%
- Food & beverage$9,79420%
- Education$21,39143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$22,797
- Lupron Depot$9,374
- XYOSTED$3,300
- PYLARIFY$1,580
- Axumin$1,400
- ZEMDRI (PLAZOMICIN)$674
- JELMYTO$533
- PROVENGE$324
- AMS 700 CXR RTE KIT$271
- AMS$149
- UroLift System$109
How this compares
$49,329 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 41 | $585,869 |
| MyrbetriqMirabegron | 355 | $247,807 |
| GemtesaVibegron | 242 | $162,087 |
| Abiraterone Acetate | 27 | $157,424 |
| XyostedTestosterone Enanthate | 91 | $67,398 |
| OrgovyxRelugolix | 14 | $38,122 |
| Tadalafil | 147 | $24,367 |
| Testosterone | 152 | $17,602 |
| AvodartDutasteride | 12 | $14,541 |
| Silodosin | 155 | $14,438 |
| AndrogelTestosterone | 20 | $13,850 |
| Tamsulosin Hcl | 843 | $12,794 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 369 | $6,553 |
| Finasteride | 504 | $5,987 |
| VesicareSolifenacin Succinate | 14 | $5,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq, Vesicare | $426 | $838,983410 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $133 | $200,209256 claims |
| Antares Pharma, Inc.Xyosted | $3,381 | $67,39891 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.